Exicure Announces Presentation at Chardan’s 6th Annual Genetic Medicines Conference Sep 1, 2022 07:00AM
UPDATE: Chardan Capital Markets Downgrades Exicure (XCUR) to Neutral Dec 13, 2021 07:50AM
Exicure to Present at the Chardan Virtual 5th Annual Genetic Medicines Conference Oct 4, 2021 05:32PM
Exicure to Present at the Chardan Virtual 4th Annual Genetic Medicines Conference Oct 5, 2020 07:00AM
Exicure Announces the Closing of its Offering of Common Stock Dec 23, 2019 04:05PM


Dec 19, 2019 09:22AM Exicure Inc. (XCUR) Prices 10M Share Common Offering at $2.75/Sh
Dec 19, 2019 09:20AM Exicure Announces Pricing of $27.5 Million Public Offering of Common Stock
Sep 3, 2019 07:00AM Exicure to Present at Upcoming Investor Conferences
Aug 2, 2019 10:21AM Exicure Announces the Closing of its Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Jul 31, 2019 08:13AM Exicure Inc. (XCUR) Prices 27.5M Share Common Offering at $2/Sh; Announces Uplisting to Nasdaq Market
Jul 31, 2019 08:08AM Exicure Announces Uplisting to Nasdaq Capital Market and Pricing of $55 Million Public Offering of Common Stock
Mar 26, 2019 01:33AM Chardan Capital Markets Starts Exicure (XCUR) at Buy
Sep 20, 2018 07:13AM Exicure, Inc. (XCUR) Reports Positive Phase 1 Results for Lead Immuno-Oncology Asset
Sep 20, 2018 07:00AM Exicure Announces Positive Phase 1 Results for its Lead Immuno-Oncology Asset